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Highlights 
- Two Mycobacterium marinum cytochrome P450s of the CYP150A subfamily were 
characterised 
 
- CYP150A5 binds a broad range of terpenoids and selectively oxidised β-ionol 
 
- CYP150A6 binds a narrower range of substrates and was structurally characterised to 
1.5 Å  
 
- Members of the CYP150A subfamily were discovered across many bacteria, 
including in pathogens 
 





Actinobacteria, including the Mycobacteria, have a large component of cytochrome P450 
family monooxygenases. This includes Mycobacterium tuberculosis, M. ulcerans and M. 
marinum, and the soil-dwelling M. vanbaalenii. These enzymes support hydroxylation of 
CH bonds and have important roles in natural product biosynthesis.  
Methods 
Two members of the bacterial CYP150 family, CYP150A5 and CYP150A6 from M. 
marinum, were produced, purified and characterised. The substrate ranges of both enzymes 
were analysed and the monooxygenase activity of CYP150A5 was reconstituted using a 
physiological electron transfer partner system. CYP150A6 was structurally characterised by 
X-ray crystallography. 
Results  
CYP150A5 was shown to bind various norisoprenoids and terpenoid. It could regioselectively 
hydroxylate β-ionol. The X-ray crystal structure of substrate-free CYP150A6 was solved to 
1.5 Å. This displayed an open conformation with short F and G helices, an unresolved F-G 
loop and exposed active site pocket. The active site residues could be identified and important 
variations were found among the CYP150A enzymes. Haem-binding azole inhibitors were 
identified for both enzymes.  
Conclusions 
Substrates were identified for CYP150A5. The structure of CYP150A6 will facilitate the 
identification of physiological substrates and the design of better inhibitors for members of 
this P450 family. Based on the observed differences in substrate preference and sequence 
variations among the active site residues, their roles are predicted to be different. 
General Significance  
Multiple CYP150 family members were found in many bacteria and are prevalent in the 
Mycobacteria including several human pathogens. Inhibition and structural data are reported 










2xYT, 2 x concentration yeast extract tryptophan broth; CYP or P450, Cytochrome P450 
enzyme; DTT, dithiothreitol; EMM, Esherichia coli minimal media; FAD, flavin adenosine 
dinucleotide; FdR, ferredoxin reductase; Fdx, ferredoxin; GC-MS or MS, gas-
chromatography mass spectrometry or mass spectrometry; IPTG, Isopropyl β-D-1-
thiogalactopyranoside; LB, Lysogeny broth (also known as Luria or Lennox Broth), 
NAD(P)H reduced nicotinamide adenine dinucleotide (phosphate); PDB, Protein Data Bank; 




Cytochrome P450s (CYP or P450) are a family of haem monooxygenase enzymes. They act 
with a conserved mechanism to selectively insert an oxygen atom from molecular dioxygen 
into a carbon-hydrogen (C-H) bond of the substrate, forming an alcohol product [1]. Various 
CYP enzymes have also been found to catalyse other oxidation reactions, such as 
epoxidation, sulfoxidation, decarboxylation, hydrogenation, and carbon-carbon bond 
formation [2]. The catalytic cycle of the enzymes requires the transfer of electrons, ultimately 
derived from NADH or NADPH, to the haem via electron transfer proteins. Bacterial CYPs 
most frequently utilise a two component electron transfer system, comprised of an iron-sulfur 
ferredoxin and a FAD-containing ferredoxin reductase, which is termed a Class 1 system [3]. 
In a given genome, the number of genes tends to decrease in the order CYP > ferredoxin > 
ferredoxin reductase [4, 5]. The reconstruction of the native electron transfer chain for a 
given CYP enzyme is often required for optimal activity, as individual CYPs are often highly 
selective for a preferred ferredoxin [6, 7].  
In humans, CYP enzymes are responsible for a large proportion of drug interactions 
but they are also widely found across plants, bacteria and fungi, performing both anabolic and 
catabolic roles [8, 9]. Due to their diversity, CYP enzymes are categorised into families, 
given a number, and sub-families, given a letter code, based on sequence similarities [10]. 
Members of the same family share >40% sequence identity, while sub-family members share 
>55%. Above 80% identity is sufficient for two enzymes to share a name. Bacterial CYPs 
have generally been investigated either as inhibition targets in pathogenic species, or as 
biocatalysts, as they frequently catalyse the formation of synthetically valuable compounds 
[9]. Functionalisation of C-H bonds is particularly difficult to achieve by chemical methods, 
often requiring harsh conditions and resulting in poor selectivity. In contrast, CYPs often 
display very high selectivity of oxidation, and regio- and stereo- selectivity in product 
formation is widespread [11].  
Mycobacterium tuberculosis, the pathogen responsible for human tuberculosis, has 
been the target of ongoing drug development efforts as increasing levels of resistance to first 
and second-line anti-tuberculosis drugs is seen globally [12]. There are 20 CYP enzyme 
encoding genes in Mycobacterium tuberculosis, several of which have been found to be 
essential for cell function or infectivity in the pathogen [13-15]. One of these, CYP121A1, 
which forms a carbon-carbon bond in the cyclic dipetide cyclo(l-Tyr-l-Tyr) has been subject 
to targeted inhibitor design [16-18]. Another, CYP128A1 has been implicated in virulence 
via the mediation of the metabolite sulfomenaquinone [19]. CYP125A1 and CYP142A1 are 
together necessary for M. tuberculosis cholesterol breakdown [20, 21]. In many other 
Mycobacterium species, the number of cyp genes is higher [22, 23]. The human pathogen 
Mycobacterium ulcerans, which causes the Buruli ulcer common in tropical areas of West 
Africa and Australia, has 24 while Mycobacterium marinum, a marine pathogen capable of 
opportunistic infection of humans, has 47 cyp genes [24, 25]. The lower number of CYPs in 
M. ulcerans and M. tuberculosis is thought to be caused by reductive evolution as they 
specialised towards pathogenicity [22-24]. M. marinum, in contrast to the two human 
pathogens, retains its ability to survive outside the host and is hypothesised to resemble the 
most recent common ancestor of M. tuberculosis and M. ulcerans, with which it shares a high 
degree of sequence identity (97% and 85%, respectively) [25]. Study of the CYP complement 
of M. marinum offers the understanding of the role and function of the additional CYPs, and 
hence the altered metabolism of the more pathogenic strains [26]. In addition, the CYPome of 
M. marinum is accompanied by a greater number of ferredoxins, with 12 single cluster 
containing species being associated with CYP enzymes in the genome [27]. Only three of 
these are retained in M. tuberculosis, while M. ulcerans retains seven.  
M. marinum M contains two members of the CYP150 family, CYP150A5 and 
CYP150A6, which are the fifth and sixth members of the same sub-family. An analogue of 
CYP150A6 is present in M. ulcerans Agy99, but neither enzyme is conserved in M. 
tuberculosis. Other members of the CYP150 family have been identified in Mycobacteria 
including in M. vanbaalenii PYR-1 (CYP150A7). This enzyme has been characterised as 
having the potential to oxidise polycyclic aromatic hydrocarbons and is therefore of interest 
for its potential application in environmental remediation [28]. The CYP150A5 gene is 
beside a ferredoxin gene in the genome, and we have previously reported the enzyme is able 
to hydroxylate the fragrance compound β-ionone when coupled with a native electron transfer 
chain [27]. Here we report the biochemical and structural characterisation of the two enzymes 




All organic substrates, derivatisation agents and other general reagents, except where 
otherwise noted, were purchased from Sigma-Aldrich, Alfa-Aesar, VWR International or 
Tokyo Chemical Industry. Antibiotics, detergents, DTT and IPTG were from Astral 
Scientific. The media for cell growth and maintenance (LB, 2xYT, SOC, EMM and trace 
elements) were prepared as reported previously [26, 29]. Antibiotics were added to the 
working concentrations listed here; ampicillin, 100 µg mL1 and kanamycin, 30 µg mL
1. 
UV-Visible spectra were recorded on a Varian Cary 5000 at 30 ± 0.5 °C. GC-MS 
analysis was performed using a Shimadzu GC-17A equipped with a QP5050A MS detector 
and DB-5 MS fused silica column (30 m x 0.25 mm, 0.25 µm) or a Shimadzu GC-2010 
equipped with a QP2010S GC-MS detector, AOC-20i autoinjector, AOC-20s autosampler 
and DB-5 MS fused silica column (30 m x 0.25 mm, 0.25 µm). On both instruments, the 
injector was held at 250 °C and the interface at 280 °C. Column flow was set at 1.5 mL min-1 
and the split ratio was 24. For norisoprenoid analysis, the initial oven temperature was 120 °C 
(held for 3 min), before increasing to 220 °C at 10 °C min-1, where it was maintained for 7 
min.  
2.2 CYP150A6 production and purification 
CYP150A6 was purified according to the same method as reported previously for 
CYP150A5, using two ion-exchange steps [27]. Before each use, the stored protein samples 
were buffer exchanged into 50 mM Tris (pH 7.4) using a PD-10 desalting column (5 mL, GE 
Healthcare) to remove glycerol. The CYP150A5 concentration was determined using ε419 = 
111 ± 4 mM−1 cm−1 [27]. The extinction coefficient of CYP150A6 was determined by the CO 
binding assay initially developed by Omura and Sato [30] which was performed as described 
previously [26]. 
2.3 Spin-state shift assays and dissociation constant determination 
The CYP enzymes were diluted to ~1 µM using 50 mM Tris (pH 7.4) buffer and the UV/Vis 
spectrum was recorded between 600 and 250 nm, while held at 30 °C. Aliquots (1 to 5 µL) of 
substrate stock solutions (50 mM or 100 mM, DMSO or EtOH) were added. The spectra were 
recorded until the shift reached a stable point. The ratio of high spin to low spin CYP (390 
nm peak to 420 nm peak) was estimated to ± 5% by comparison to the P450cam–camphor 
bound substrate spectra [26].  
To measure the binding affinity, the CYP enzymes were diluted to ~2 µM in a volume 
of 2.5 mL in 50 mM Tris (pH 7.4) buffer and used to baseline the spectrophotometer. 
Varying aliquots (1 to 3 µL) of substrate stock solutions of increasing concentrations (1 mM, 
10 mM or 100 mM) were added via a Hamilton syringe and mixed. The difference spectrum 
was recorded between 300 nm and 600 nm. Further aliquots of substrate were added until no 
change in the peak-to-trough ratio at 420 nm and 390 nm (for a Type I spectrum) or 410 
and 430 nm (for a Type II spectrum) was observed. The difference in absorbance versus 
substrate concentration was fitted to the hyperbolic function (Equation 1):  




where Kd is the dissociation constant, [S] is the substrate concentration, ΔA the peak-to-
trough ratio, and ΔAmax the maximum peak-to-trough absorbance. Where a particular 
substrate exhibited tight binding (Kd equalling less than five times the concentration of the 
enzyme), the data were instead fitted to the tight-binding quadratic equation: 
∆𝐴 =  𝛥𝐴 ×
[𝐸] + [𝑆] + 𝐾𝑑 − √([𝐸] +  [𝑆] + 𝐾𝑑)
2 − 4[𝐸][𝑆] 
2[𝐸]
 
where Kd is the dissociation constant, [S] is the substrate concentration, ΔA the peak-to-
trough ratio, ΔAmax the maximum peak-to-trough absorbance and [E] is the enzyme 
concentration [31]. 
2.4 Whole-cell oxidation turnovers 
Whole-cell turnovers with CYP150A5 were performed as per the method previously reported 
[26]. Briefly, a pRSFDuet vector containing the genes of the CYP and Fdx8, and a pETDuet 
vector containing the Fdx8 and FdR1 genes used for expression in E. coli BL21(DE3) cells. 
These were grown in LB with the appropriate antibiotics and trace elements (3 mL L-1) at 37 
°C. Alternative pETDuet vectors were used containing genes for the electron transfer partners 
listed in Table S1. Once the cells reached late log phase, the temperature was reduced to 18 
°C. Benzyl alcohol (0.02% v/v), ethanol (2% v/v) were added and protein expression was 
induced after a further 30 min with IPTG (0.1 mM). After 16 h, the cells were resuspended in 
E. coli minimal media (EMM) and the substrates added to a final concentration of 1 mM and 
shaken for a further 24 h. Aliquots of these growths (including cells) were extracted into ethyl 
acetate, and analysed by GC-MS. 
2.5 Phylogenetic analysis 
Sequences were obtained either from the National Centre for Biotechnology Information 
(NCBI) database or from the Dr Nelson P450 homepage for bacterial P450s [32]. Sequence 
alignments were performed using ClustalW [33]. The evolutionary history was inferred by 
using the Maximum Likelihood method based on the Jones-Taylor-Thornton (JTT) matrix-
based model [34]. Initial trees for the heuristic search were obtained automatically by 
applying Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances estimated 
using a JTT model, and then selecting the topology with superior log likelihood value. The 
tree is drawn to scale, with branch lengths measured in the number of substitutions per site. 
All positions containing gaps and missing data were eliminated. Evolutionary analyses were 
conducted in MEGA6 [35]. 
  
2.6 Crystallography 
CYP150A5 and CYP150A6 underwent a further purification step by size exclusion (Enrich 
SEC Column, 650 x 10 x 300 mm, 1 mL min-1) before concentration to ~30 mg mL-1  in 50 
mM Tris (pH 7.4). Commercially available screening conditions (Hampton Research) were 
used for initial screening in 96 well sitting drop trays, using 1 µL of both protein and 
reservoir solution. Crystal conditions were then refined using the hanging drop vapour 
diffusion method, again using both 1 µL of protein and reservoir solution with a 500 µL 
reservoir. Diffraction quality crystals of CYP150A6 were obtained after 2 weeks at 16 °C 
from the condition containing 0.2 M ammonium phosphate, 20% w/v polyethylene glycol 
3,350, pH 4.7. The crystals were harvested using a Micromount (MiTeGen) and cryo-
protected by immersion in Parabar 10312 (Paratone-N, Hampton Research) before flash 
cooling in liquid N2. Data were collected by X-ray diffraction at the Australian Synchrotron 
MX1 beamline (360 exposures using 1° oscillations at a wavelength of 0.9357 Å) at 100 K 
[36]. The data were processed into the space group P3121 using iMosflm [37], followed by 
truncation and addition of Rfree flags using Aimless [38], as part of the CCP4 package [39]. 
Molecular replacement phasing was carried out using the MrBump pipeline [40], also part of 
CCP4, comprising PhaserMR [41] and one round of Buccaneer [42] model building and 
refinement. The search model used was PDB:3EJD [43], prepared for molecular replacement 
by MOLREP [44]. The model was rebuilt using Coot [45] based on initial electron density 
maps and refined using phenix.refine [46] over several iterations. The structure was deposited 
in the Protein data bank (PDB: 6DCB) and the data collection and refinement statistics are 
presented in Table 1.  
 
Table 1: Crystal data collection and refinement statistics for CYP150A6 from M. marinum 
(PDB: 6DCB) 
Data collection statisticsa 
Wavelength  0.95370 
Unit cell a = 80.57 b = 80.57 c = 134.76 
α =  90 β = 90 γ = 120  
Space group  P3121  
Mol. in asym. unit  1 
Resolution 48.47 – 1.55 (1.57 – 1.55)b  
Unique reflections 74838 (3655) 
Completeness  100.0 (100.0) 
Redundancy 22.0 (20.7)  
(I)/[σ(I)] 11.7 (0.8) 
Rmerge (all I+ and I-) 0.26 (4.72) 
Rpim (all I+ and I-)  0.057 (1.056) 
CC(1/2)  0.99 (0.36) 
Rwork 0.223 (0.342) 
Rfree 0.247 (0.349) 
% solvent 53.46 
Residues modelled  406 
RMS deviation from restraint values 
Bond lengths  0.004 
Bond angles 0.80 
Ramachandran analysis 





a Data collected from one crystal 




3.1 Phylogenetic analysis  
The CYP150 family has only one named subfamily at present (according to the Cytochrome 
P450 Homepage maintained by Dr Nelson of the University of Tennessee [32]). There are 15 
members of the subfamily that have been assigned CYP names so far, all of which are found 
in either Mycobacterium or Frankia species. CYP150A5 and CYP150A6 are both found in 
M. marinum M, with a CYP150A6 species also found in M. ulcerans Agy99 (98% sequence 
identity). Other Mycobacterium species such as M. vanbaalenii PYR-1, M. smegmatis MC2 
155, M. avium sp. paratuberculosis and M. kansasii ATCC 12478 contain more than one 
CYP150 family member. In some species up to six genes encoding CYP150 family members 
can be found [23]. For example M. vanbaalenii PYR-1 has four, CYP150A7-10. As such, the 
CYP150 family appears prolific in Mycobacterium species, including human pathogens M. 
ulcerans and M. colombiense (Table S2). A BLAST search revealed there are a large number 
(~1000 entries with >55% identity) of similar proteins to both CYP150A5 and CYP150A6, 
the vast majority of which are from Mycobacterium (>90% of entries found). Enzymes of this 
family are also found in species of Frankia, Streptomyces, Nocardia, and Rhodococcus (see 
Table S2 for more details). This distribution of analogous enzymes in other Actinobacteria is 
similar to that observed for the M. marinum CYP enzymes CYP268A2 and CYP147G1 [26, 
27, 47]. The analysis of Parvez et al placed the CYP150 family in a clan with the other 
Mycobacterium P450 families of CYP278, CYP1016, CYP269, CYP121, CYP1120, 
CYP1126, and CYP144 [23].  
A sequence alignment of CYP150 family members (selected enzymes shown in Fig. 
S1) showed the proximal cysteine is conserved as Cys363 (the residue numbering is given for 
CYP150A6 which coincidentally is the same for CYP150A5) as is the nearby phenylalanine 
(Phe356). The EXXR motif is also conserved in all the CYP150 enzymes analysed (Fig. S1). 
All contain an acid-alcohol pair; a glutamate (Glu255) and a threonine (Thr256). 
Phylogenetic analysis revealed CYP150A6 clusters closer to the previously studied M. 
vanbaalenii PYR-1 CYP150A7 (the polycyclic aromatic hydrolase [28]) and A8, while 
CYP150A9 and A10 are closer to CYP150A5 (Fig. 1). There appears to be two distinct 
CYP150 family groups; one containing CYP150A5 and the other with CYP150A6. However, 
all the CYP150 family members cluster together compared to the closest structurally 
characterised enzymes CYP144A1 from M. tuberculosis (32% identity to CYP150A5) and 
P450BioI from Bacillus subtilis (30% identity to CYP150A6). 
 
Figure 1: Phylogenetic tree (phenogram) of M. marinum enzymes CYP150A5 and 
CYP150A6 alongside other members of the CYP150 family from various Mycobacterium 
and other species. CYP150A7 from M. vanbaalenii has been reported to bind polyaromatic 
hydrocarbons. The CYP150 family member from Frankia sp. EuI1c (encoded by the gene 
FraEuI1c_5334) is included. The scale shows number of substitutions per site. CYP150A11, 
A12, A13 and A14 are from Frankia sp. EAN1pec. 
The genomic context of the two CYP enzymes in M. marinum M is dissimilar (Fig. 
S2). CYP150A5 (Mmar_4737) lies near CYP190A3 (Mmar_4733) and there are three [3Fe-
4S] ferredoxins nearby: Mmar_4730, Mmar_4734 and Mmar_4736. M. liflandii 128FXT, M. 
avium sp. paratuberculosis, M. smegmatis MC2 155 and other Mycobacterium species show 
similar gene neighbours in the region of their CYP150A subfamily analogues. These  also 
include a TetR transcriptional regular, an acyl-CoA dehydrogenase, an acyl-CoA 
acetyltransferase and an amidohydrolase. CYP150A9 from M. vanbaalenii PYR-1 has the 
most similar genomic region to that of CYP150A5 of the four CYP150 members from that 
species. In contrast, while CYP150A6 is present in M. ulcerans Agy99 (the sequence identity 
is 98%), comparison of the surrounding genomic region shows the enzyme is not part of a 
conserved operon. In M. ulcerans Agy99 CYP188A3 is nearby (three genes upstream) 
accompanied by a ferredoxin, while in M. marinum M the equivalent pair of genes are 23 
genes downstream from CYP150A6. Frankia species that contain CYP150 family members 
show very little regional genomic similarity to M. marinum M (Fig. S2). 
3.2 Characterisation of the CYP150 enzymes  
The production, purification and quantitation of CYP150A5 has been reported previously in 
an investigation of the ferredoxin association with the CYPome of M. marinum [27]. 
CYP150A6 was produced recombinantly using E. coli, purified and the ferrous CO bound 
spectrum was recorded (mass confirmed by SDS-PAGE, Fig. S3). The absorbance of the 
enzyme’s Soret peak shifts (>95%) to 450 nm upon reduction and CO exposure, indicating 
the reconstituted protein is a viable P450 enzyme (Fig. 2). The CYP150A6 enzyme 
demonstrated a comparable shift of the ferrous-CO bound form to CYP150A5 [27] and the 
extinction coefficient was determined to be ε418=110 ± 6 mM
−1 cm−1. 
In order to determine the substrate range, other members of the CYP150 family were 
considered. CYP150A7 from M. vanbaalenii has been reported to oxidise polyaromatic 
hydrocarbons, such as pyrene, dibenzothiophene, and 7-methylbenz-α-anthracene [28]. 
However, as Brezna et al reported, there is no correlation between presence of a member of 
the CYP150 family and the polycyclic aromatic degradation ability of a particular strain, 
suggesting this may be a promiscuous activity of the enzyme [28]. 
 
Figure 2: CYP150A6 (black, A418), the reduced ferrous (blue, A417) and the ferrous form 
bound with CO (red, A446) showing the characteristic ~450 nm absorbance. The shoulder at 
~420 nm comprises < 5% of the total area. The extinction coefficient for the enzyme was 
determined to be ε418 = 110 ± 6 mM
−1 cm−1. 
The first substrates tested with both enzymes were therefore aromatic and polycyclic 
substrates. These included bicyclic aromatics such as naphthalene, naphthol, phenylphenol, 
tetralin, and quinoline. None perturbed the spin state of the CYP150A5 enzyme by more than 
15% (see Table S3). Ionone derivatives such as α- and β-ionol, camphor and cineole as well 
as larger molecules such as sclareol and sclareolide were then assessed as substrates (Fig. 3). 
A large range of norisoprenoid substrates were capable of shifting the spin state shift of 
CYP150A5 to the high spin state (Table 2). These substrates included α-ionol (70% HS), 
methyl-α-ionone (65%), and α-ionone (45%). Interestingly, β-damascone, which differs in the 
location of the ketone group by only two carbons to the ionone substrates, shifted only 15% 
of the haem to the high spin form (compared to 60% high spin with β-ionone). (S)-(‒)-
Camphor (60%) and other monoterpenoid substrates such as bornyl acetate and isobornyl 
acetate (75% and 70% respectively) also induced shifts indicative of a good substrate fit with 
the active site of the enzyme. The diterpene sclareol induced the highest spin state shift, at 
90%, compared to 50% by sclareolide, which has an additional ring in the structure (Fig. 3). 
In contrast to the other hydrophobic aromatic compounds assessed, the bicyclic sesquiterpene 
guaiazulene shifted 60% of the haem to the high spin form. Both guaiazulene and 2-naphthol 
(70% high spin) were better substrates than 2-methylnapthalene (10%) suggesting the 
substituents around the aromatic ring are important to substrate recognition in CYP150A5. 
Table 2: Substrate binding data for both CYP150A5 and CYP150A6. See Figure 4 for 
dissociation constant analysis. The Supplementary Information contains binding data of 
additional substrates (Table S3, Fig. S4 to S8). 
Substrates 
CYP150A5 Spin 




Spin state shift (%) 
Sclareol 90 0.8 ± 0.08 10 
Bornyl acetate 75 45 ± 6 10 
Isobornyl acetate 70 34 ± 2 20 
α-Ionol 70 17 ± 2 10 
2-Naphthol 70 1900 ± 280 <5 
Methyl-α-ionone 65 23 ± 4 10 
Guaiazulene 60 1.9 ± 0.4  <5 
β-Ionone 60 41 ± 2 [27] 15 
1,8-Cineole 60 331 ± 45 <5 
Fenchyl acetate 60 88 ± 13  10 
β-Ionol 55 64 ± 6 20 
Sclareolide 50 - 25 
(-) indicates dissociation constant was not determined due to limitations in substrate solubility 
preventing the endpoint being reached.  
Dissociation constant analyses were performed for compounds that, from the spin 
state shift, indicated they were complementary to the active site of CYP150A5 (defined here 
as where the shift to the high spin form was greater than 60%, Fig. 4). Sclareol had the 
highest binding affinity for the enzyme, at 0.8 ± 0.08 µM, followed by guaiazulene with 1.9 ± 
0.4 µM. These were almost an order of magnitude higher than the next best, α-ionol (17 ± 2 
µM). The previously reported affinity with β-ionone (41 ± 2 µM [27]) was similar to those 
recorded for bornyl acetate (45 ± 6 µM) and slightly weaker than with isobornyl acetate (34 ± 
2 µM). β-Ionol was less tightly bound (64 ± 6 µM). Despite the high spin state shifts recorded 
for naphthol and cineole with the enzyme, the dissociation constants indicated they bound 
weakly (1900 ± 280 µM and 331 ± 45 µM for 2-naphthol and 1,8-cineole, respectively). The 
results of this binding analysis provide evidence for a substrate range for CYP150A5 that 
includes both polycyclic hydrocarbons and terpenoid substrates.  
 
Figure 3: Structures of selected substrates tested with CYP150A5 and CYP150A6. 
CYP150A6, in contrast, did not demonstrate any significant shifts in the spin state (all 
≤ 25%) with any substrate tested. Sclareolide (25%), 1,4-cineole (20%), isobornyl acetate 
(20%) and β-ionol (20%) were the substrates that induced the greatest spin state shifts. A 
range of other substrates were tested, including fatty acids, benzoic acids, terpenoids, 
aromatics and steroids, however, no significant spin state shift was recorded (all ≤ 20%, 
Table S3 and Fig. S7). The CYP150A6 enzyme requires further characterisation as this 
screening method did not reveal many substrates which were able to modify the spin state. 
This may suggest that the binding of the physiological substrate for this enzyme may be 









Figure 4: Dissociation constant analysis of CYP150A5 with (a) sclareol, (b) guaiazulene, (c) 
β-ionol and (d) ketoconazole. The inset represents a typical substrate titration. The peak to 
trough difference in absorbance was measured for (a) and (c), from 420 to 390 nm, for (b) 
trough to baseline (420 to 600 nm) due to interfering substrate absorbance and for (d) 432 to 
411 nm. For additional dissociation constant analyses see Figure S5 and S6.  
Both enzymes were tested with a range of azole compounds, known competitive 
inhibitors of CYPs (Fig. 5, Fig. S6 and Fig. S8). Econazole, ketoconazole and miconazole 
among others, generated Type II shifts in both enzymes indicative of N binding directly (or 
indirectly via a bridging H2O ligand) to the haem Fe (Table 3).  Both 1- and 4-
phenylimidazole gave inhibitory shifts in both CYPs, while 2-phenylimidazole did not, 
similar to the results obtained with CYP268A2 and other P450 enzymes [26, 48, 49]. 
Fluconazole bound to CYP150A5, shifting the absorbance in a Type II manner, while with 
CYP150A6 a small (HS ~5%) Type I shift was observed suggesting it bound the enzyme in a 
substrate-like manner. In general, the phenylimidazoles bound less tightly, with dissociation 
constants in the tens of µM for both enzymes in contrast to the nanomolar affinities of the 
larger azoles.  









1-Phenylimidazole type II, 423 nm 19.2 ± 5.1 type II, 423 nm 29.9 ± 13.2 
2-Phenylimidazole ~ 0% - ~ 0% - 
Clotrimazole type II, 424 nm 0.016 ± 0.01 type II, 425 nm 0.05 ± 0.02 
Econazole type II, 424 nm 0.01 ± 0.01 type II, 424 nm 1.1 ± 0.06  
Fluconazole type II, 419 nm - Type 1, ~5% - 
Ketoconazole type II, 423 nm 0.80 ± 0.14 type II, 422 nm 6.6 ± 1 
Miconazole type II, 424 nm 0.045 ± 0.01 type II, 423 nm 1.0 ± 0.09 
(-) indicates dissociation constant was not determined.  
The affinity of the azoles were higher for CYP150A5 than CYP150A6 (for example, 
with econazole KD = 0.01 ± 0.01 µM compared to 1.1 ± 0.06 µM for the respective enzymes). 
The affinity of clotrimazole for CYP150A6 was high in comparison to the other tested azoles 
with that enzyme (KD = 0.05 ± 0.02 µM, two orders of magnitude tighter than the next best) 
although the CYP150A5 affinity (0.016 ± 0.01 µM) was greater still.  
  
(a) (b) 
Figure 5: Dissociation constants of CYP150A6 with (a) ketoconazole and (b) clotrimazole. 
The inset represents a typical substrate titration. The peak to trough difference in absorbance 
was measured from was (a) 435 to 414 nm and (b) 434 to 413 nm. For additional 
dissociations constants see Figure S8. 
 3.3 Product formation  
Reconstitution of the in vivo activity of CYP150A5 was attempted with the native ferredoxin 
Fdx8 (Mmar_4736) as it is the adjacent gene to the CYP. No reductase gene is located nearby 
so the ferredoxin reductase FdR1 (Mmar_2931), which has been demonstrated to support 
CYP147G1 activity with Fdx3, was used [27]. Additional electron transfer systems including 
Tdx/ArR [7, 50], the fused phthalate dioxygenase reductase (PDR) domain from 
Pseudomonas putida pp_1957 [51], and other native ferredoxins from M. marinum were also 
tested (see Table S1). This included the ferredoxin seven genes away from CYP150A5, Fdx6 
(Mmar_4730).  The product formation of each electron transfer system was tested with the 
substrate β-ionone. The native Fdx8 in combination with FdR1 was the best system tested.  
 
Figure 6: GC chromatogram of the in vivo turnover of CYP150A5 with Fdx8 and FdR1 (red) 
and the alternative electron transfer system of pp_1957 from Pseudomonas putida (blue) [51] 
both with the substrate β-ionol. β-Ionol (RT 6.9 min) converted into a single hydroxylation 
product, 4-hydroxy-β-ionol (RT 9.4 min). The physiological electron transfer partners Fdx8 
and FdR1 supported greater CYP activity than the alternative systems tested, including 
pp_1957 (shown above, see Table S1 for others). * indicates a substrate impurity.  
A range of substrates were tested with the CYP150A5 enzyme, including β-ionol and other 
terpenoids. A single hydroxylation product of β-ionol with CYP150A5 was visible by GC-
MS analysis (Fig. 6). The mass spectrum and retention time corresponded to the 4-hydroxy-
β-ionol product previously using CYP101B1 (Fig. S9)[52]. This is consistent with the 4-
hydroxy product of β-ionone with the same enzyme. Again higher levels of metabolite 
formation were observed in combination with the Fdx8/FdR1 electron transfer partners (Fig. 
6). However, product formation levels were still low and metabolites could not be detected 
with other substrates using the in vivo systems. Given the [3Fe-4S] Fdx8 ferredoxin is located 
nearby in the genome, the barrier to efficient electron transfer and oxidation may arise from 
the ferredoxin reductase. Further investigation into potential alternative reductases is required 
to optimise the system and to establish the full range of products that are generated.  
 
Scheme 1: CYP150A5 conversion of β-ionol to 4-hydroxy-β-ionol.  
 
3.4 Crystal structure of CYP150A6 
In order to better understand the substrate range of both enzymes we attempted crystallisation 
of both CYP150A5 and CYP150A6 in a range of conditions. No crystals were obtained for 
CYP150A5, but diffraction quality crystals were obtained for substrate-free CYP150A6. Data 
for CYP150A6 were collected from one crystal and the structure solved to 1.5 Å (Table 1, 
PDB: 6DCB). The structure presented difficulties in phasing that were resolved by using a 
truncated model of P450BioI prepared by Sculptor (as CYP150A6 lacks the acyl-carrier 
domain of the P450BioI structure) [43]. Several regions required full rebuilding in Coot before 
refinement (residues 67 to 76 and 350 to 360). The final structure modelled the enzyme from 
residues 3 to 424 with the exception of the residues from 180 to 195 of the F-G loop for 
which the electron density was unresolved (Fig. 7). Despite the missing 16 residues, the 
overall structure of the enzyme clearly displays the conserved fold of a P450 with an open 
structure when compared to other structures in the PDB (composite omit map Fig. S10, and 
structural comparisons in Fig. S11 and S12). The disorder in the F-G loop is relatively 
common in previously characterised P450 enzymes in the open form [53, 54]. Both the F and 
G helices in CYP150A6 appear to be shorter than in most structurally characterised P450 
isoforms (Fig. 7(b)), leaving a probable 18 residue long F-G loop region (in contrast M. 
tuberculosis CYP144A1 has only 3 residues between the F and G helices, Fig. S12). The 
proline residue at the end of the G helix (P199) is conserved in all Mycobacterium CYP150 
members, while the glycine at the end of the F helix (G180) is conserved in M. ulcerans 
CYP150A6 and M. vanbaalenii CYP150A7, but not in CYP150A5 and some others, inferring 
that in these proteins the F helix may be longer. The length of the F and G helices is similar 
to those in mammalian CYP3A4, which has a large degree of substrate promiscuity [55, 56]. 
However the F-G loop region in CYP3A4 contains two further helices (F´ and G´) and is 35 
residues long. As a result of the unresolved residues in CYP150A6, interpreting the precise 
nature of the active site and access channel is more challenging. As modelled, the active site 
appears to be very open to solvent (Fig. S13). The F and G helices may reform to a length 
similar to those in other systems when the enzyme is crystallised in the presence of a 
substrate.  
The structure was compared to that of P450BioI (PDB: 3EJD), but the active site of the 
two structures present few similarities apart from the overall fold when overlaid (Fig. S12 
and S15). An overlay with the closest structural model from M. tuberculosis, CYP144A1 (as 
identified using MrBump and also the Dali server [57]) showed two regions of dissimilarity, 
including small α-helices (between the α-B and B´ region, and the other between α-L and β-
5) that are not present in CYP144A1 [58]. These are referred to in this text as L´ and B ̋ (Fig. 
7(a)). The remaining best matches as identified by the Dali server were Bacillus megaterium 
CYP109A2 (PDB: 5OFQ)[59] and M. tuberculosis CYP142A1 (PDB: 2XKR). The β-sheet 
region in the B-C loop of CYP144A1 was absent in CYP150A6 (Fig. S11). The B-C loop 
area was more similar to that of the M. smegmatis CYP142A2 enzyme (PDB: 3ZBY, Fig. 
S12) [60].  
(a) (b)  
 (c)  
Figure 7: (a) CYP150A6 resolved to 1.5 Å with labelled α-helices according to the 
nomenclature developed in P450cam  (CYP101A1) [61]. Helices are coloured in red, β-sheets 
in yellow and the remaining backbone in green. The haem is in blue. The two additional 
helices of CYP150A6 are labelled in red. In the absence of substrate a water molecule binds 
to the distal site of the haem Fe. (b) The key residues P199 and G180 at the end of the F and 
G helices showing the short F and G loops (for comparison to other P450 structures see 
Figures S11 and S12). (c) The residues as well as the network of water molecules (hydrogen 
bonds in red) in the active site of the substrate-free CYP150A6 (green) enzyme. 
The distal side of the haem contains an iron-bound water molecule (Wat316, Fe-O 
2.2Å). Wat316 is stabilised by a network of hydrogen bonded waters in the active site (Fig. 
7(c)). Two further water molecules (Wat110 and Wat10) are found bound in the kink of the I 
helix, forming hydrogen bonds between the A251 and T256 residues (where the T256 and 
E255 are the acid-alcohol pair of the enzyme, Fig. S14). The substrate binding pocket is 
primarily non-polar although the polar residues S301, D302 and M94 are present. The D302 
residue, however, interacts with the carboxylate group of the haem (analogous to D297 in 
P450cam [62]). These, along with A64 and L65, V99, F248, A251 and A252, V299, and I409 
can be identified as probable active site residues. The residues between 248 and 252 belong 
to the I helix (as seen in Fig. S14) while the B-C loop provides M94 and V99. As the residues 
of the F-G loop that may have formed the cap of the active site are not modelled, their 
probable interactions with a ligand cannot be seen. However, there is only limited evidence 
for direct substrate interaction with the F-G loop [63].  
Applying the sequence alignment of CYP150A5 and other CYP150 enzymes to the 
structure of CYP150A6 allows the identification of the probable active site residues of those 
species (Table 4). The residues are very dissimilar between CYP150A6 and CYP150A5. 
Instead of the A251, CYP150A5 has a serine residue (the residue numbering in both enzymes 
is aligned so will not be given) while the S301 residue of CYP150A6 is changed to a glycine. 
F248 is changed to asparagine, while both the V99 and M94 residues are replaced with a 
phenylalanine. A64 and L65 are a serine and valine respectively in CYP150A5. Of the 
residues identified above, only the acid alcohol pair (E255 and T256), V299, D302 (which 
interacts with a haem carboxylate) and I409 are conserved in both enzymes. Together the 
changes would represent a significant alteration in the polarity and shape of the active site 
between the enzymes, as reflected in the substrate binding results obtained for the two CYP 
isoforms.  
Table 4: The active site residues of CYP150A6 and the aligned residues of other CYP150 
family members, including CYP150A6 from M. ulcerans, CYP150A5 from M. marinum and 
all four enzymes from M. vanbaalenii PYR-1. Bold indicates the residue matches that of 
CYP150A6, underlined indicates it matches CYP150A5. For emphasis those that are 

















A64 A64 S64 S65 A64 A64 S65 A70 
L65 L65 V65 V66 V65 I65 V66 V71 
M94 M94 F94 F96 M94 I94 F98 F100 
V99 V99 P99 P101 V99 V99 P103 P105 
F248 F248 N248 N250 F253 F250 N252 N253 
A251 A251 S251 S253 A256 A253 S255 A256 
A252 A252 A252 A254 A257 A254 A256 A257 
V299 V299 V299 V301 V304 T301 V303 I304 
I409 I409 I409 I411 I414 L411 I413 I414 
a E255 and T256 (the acid alcohol pair) are also conserved in all but are not listed here. 
 
The CYP150A6 enzyme in M. ulcerans Agy99 preserves all of the active site residues of the 
M. marinum equivalent, so it would be expected to both perform a similar function and the 
same inhibitors would be effective. Of the M. vanbaalenii PYR-1 enzymes, CYP150A7 has 
all the CYP150A6 active site residues conserved. CYP150A9 has equivalent residues to 
CYP150A5 at all these positions as does CYP150A3 from M. smegmatis MC2 155 (Table 4 
and see Table S4 for other CYP150 family enzyme comparisons). The remaining two 
isoforms of M. vanbaalenii PYR-1, CYP150A8 and CYP150A10, share some active site 
residues with both M. marinum enzymes, and potentially would have distinct roles again.   
4. Conclusions 
Members of the CYP150 family are widely found in Mycobacterium species, as well as in 
related Actinomycetes. The only previously studied member of the family, CYP150A7 from 
M. vanbaalenii PYR-1, was found to oxidise certain polycyclic aromatic hydrocarbons which 
was linked to the activity of this species to degrade this class of compound. Here, the enzyme 
CYP150A5 is shown to bind and hydroxylate cyclic terpenes, with sclareol having the best 
binding parameters, rather than polycyclic aromatics. A physiological ferredoxin was used to 
support CYP activity in combination with a ferredoxin reductase also from M. marinum. The 
structural characterisation of CYP150A6 will facilitate future substrate identification for this 
enzyme through use of modelling and high-throughput screening methods. As both enzymes 
are found in a range of Mycobacteria, including human pathogens, the inhibitors which were 
determined for both enzymes could be used to stop CYP-related metabolism in these species 
which could form the basis of future drug design.   
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